皇冠足球app(www.hg108.vip):Sanofi ends cancer drug trials

admin 1个月前 (08-26) 社会 16 0

皇冠足球appwww.hg108.vip)是一个开放皇冠即时比分、代理最新登录线路、会员最新登录线路、皇冠代理APP下载、皇冠会员APP下载、皇冠线路APP下载、皇冠电脑版下载、皇冠手机版下载的皇冠新现金网平台。皇冠官网平台上登录线路最新、新2皇冠网址更新最快,皇冠体育APP开放皇冠会员注册、皇冠代理开户等业务。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

皇冠体育官网www.hg108.vip)是一个开放皇冠正网即时比分、皇冠官方的平台。皇冠体育官网(www.hg108.vip)提供最新皇冠登录,皇冠体育官网包含新皇冠体育代理、会员APP,提供皇冠官网代理开户、皇冠官网会员开户业务。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。
allbet声明:该文看法仅代表作者自己,与本平台无关。转载请注明:皇冠足球app(www.hg108.vip):Sanofi ends cancer drug trials

网友评论

  • (*)

最新评论

文章归档

    站点信息

    • 文章总数:8435
    • 页面总数:0
    • 分类总数:8
    • 标签总数:2189
    • 评论总数:6666
    • 浏览总数:631169